Drug Trial Radar · NCT07301034
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Nov 14, 2028
Study completion Feb 24, 2029
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Dec 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque. The purpose of the study is to determine whether ziltivekimab can effectively reduce this plaque. Participants will either receive ziltivekimab (the active medicine) or a placebo (a dummy medicine with no effect on the body), with the treatment assignment decided by chance. It is important to note that ziltivekimab is not yet approved in any country or region worldwide; therefore, it is a new medicine that doctors cannot prescribe. The study will last for about 15 months.
Conditions
- Myocardial Infarction
Interventions
ZiltivekimabDrug
Participants will receive ziltivekimab subcutaneously.
Ziltivekimab PlaceboDrug
Participants will receive placebo matched to ziltivekimab subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interestTime frame: From randomisation (week 0) to end-of-study (52-week)
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Medizinische Universität Wien
Vienna, Austria · Not yet recruiting
Aalborg Universitetshospital Hjertemedicinsk Afdeling
Gistrup, Denmark · Not yet recruiting
Rigshospitalet - Kardiologisk Forskningsenhed
København Ø, Denmark · Not yet recruiting
Ospedale Policlinico San Martino
Genova, Italy · Not yet recruiting
AOU Maggiore della Carità di Novara - Dipartimento Toraco-Cardio-Vascolare - SCDU Cardiologia
Novara, Italy · Not yet recruiting
Azienda Ospedaliera Universitaria San Luigi Gonzaga - S.C.D.O. Microcitemie e malattie rare ematologiche
Orbassano, Italy · Not yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Rome, Italy · Not yet recruiting
IRCCS Policlinico San Donato
San Donato Milanese, Italy · Not yet recruiting
Azienda Ospedaliera San Giovanni Addolorata
Rome, Lazio, Italy · Not yet recruiting
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, Lombardy, Italy · Not yet recruiting
DAI Scienze Mediche - UOC Endocrinologia
Messina, Sicily, Italy · Not yet recruiting
Presidio Ospedaliero di Rivoli
Rivoli, To, Italy · Not yet recruiting
Radboudumc
Nijmegen, Netherlands · Not yet recruiting
Erasmus MC
Rotterdam, Netherlands · Not yet recruiting
Hospital Universitario de la Princesa
Madrid, Spain · Not yet recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Spain · Not yet recruiting
Universitäres Herzzentrum
Basel, Switzerland · Recruiting
Inselspital-Universitätsklinik für Kardiologie
Bern, Switzerland · Recruiting
HUG-Service de Cardiologie
Geneva, Switzerland · Not yet recruiting
LUKS-Herzzentrum
Lucerne, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.